Ahmed Sobhy

Ahmed Sobhy

Auto-generated profile, based on publicly available information

Ahmed Sobhy

Faculty of Medicine Kafr‐Elsheikh University Kafr‐Elsheikh Egypt

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2025 in ASIDE Case Reports
Verified
Journal Article
Open access
MMMohamed Reyad Mohamed
Mohamed Reyad Mohamed
MMMohamed R. Murad
Mohamed R. Murad
ASAhmed Sobhy
Ahmed Sobhy
AHAhmed Magdy Hassan
Ahmed Magdy Hassan
ONOmar Nassar
Omar Nassar
Noonan syndrome (NS) is a genetic disorder caused by mutations in the RAS/MAPK signaling pathway, typically characterized by unique physical features, congenital heart defects, and short stature. Osteoporosis (OP), although uncommon in NS, can significantly impact patients' quality of life. We report the case of a 60s-year-old male with NS who experienced progressive osteoporosis over seven years. Dual-energy X-ray absorptiometry (DEXA) scans revealed a marked decline in bone mineral density (BMD) accompanied by multiple fractures. Despite normal vitamin D and parathyroid hormone intact levels, the patient’s BMD continued to deteriorate, leading to vertebral compression fractures that necessitated surgical intervention. This case highlights the importance of early osteoporosis screening and prompt management in NS patients to prevent severe complications. Further research is warranted to explore the mechanisms underlying bone fragility in NS and to develop targeted therapeutic strategies.

25 August 2025 in Journal of Chest Surgery
Verified
Journal Article
Open access
PDF file
ANAhmed Nazmy
Ahmed Nazmy
MGMohamed Hesham Gamal
Mohamed Hesham Gamal
HEHesham Elharti
Hesham Elharti
ASAhmed Sobhy
Ahmed Sobhy
ASAhmed Yasser Shaban
Ahmed Yasser Shaban
Ahmed Nazmy, M.D., Mohamed Hesham Gamal, M.D., Hesham Elharti, M.D., Ahmed Sobhy, M.D., Ahmed Yasser Shaban, M.D.. J Chest Surg -0001;0:. https://doi.org/10.5090/jcs.25.056

19 July 2026 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Open access
PDF file
ASAhmed Sobhy
Ahmed Sobhy
TKTawfiq Khurayzi
Tawfiq Khurayzi
ANAhmed Nazmy
Ahmed Nazmy
HEHussein A. El-Shirbeny
Hussein A. El-Shirbeny
MEMahmoud Abd El-Nasser
Mahmoud Abd El-Nasser
HEHaitham H. Elfarargy
Haitham H. Elfarargy
Purpose: In the past, cochlear implantation (CI) was not commonly offered to this population due to concerns about limited auditory rehabilitation outcomes. Recent advancements in CI technology and multidisciplinary rehabilitation have expanded candidacy, but outcomes in deafblind patients remain underexplored. This systematic review and meta-analysis aimed to synthesize available evidence on CI outcomes in deafblind individuals. Methods: Data sources included PubMed, Web of Science, Scopus, and Cochrane Library from inception to July 20, 2025. Observational studies included adults or children with confirmed dual sensory impairment after CI. Primary outcomes included speech clarity (Speech Intelligibility Rating [SIR]), verbal communication ability, and telephone communication competence. Secondary outcomes encompassed audiological performance, auditory and cognitive development, educational integration, psychological benefits, and advanced auditory skills. Risk of bias was examined using the NIH Quality Assessment Tool and Newcastle–Ottawa Scale. STATA 18 was used to perform random-effects meta-analyses. Results: Thirty-six studies were analyzed, including 491 patients (mean age 23.68 years; 23% male). The pooled mean SIR score was 3.45 (95% CI: 2.69–4.21), with no significant difference between Usher and non-Usher groups ( p = 0. 52). Verbal communication ability was achieved in 70% (95% CI: 0.60–0.79), while telephone communication competence was limited to 51% (95% CI: 0.33–0.69). Conclusion: Cochlear implantation is an effective intervention for deafblind individuals, demonstrating significant improvements in speech intelligibility and verbal communication regardless of the underlying etiology (Usher vs. non-Usher). While verbal communication rates are promising, advanced skills such as telephone competence remain limited, suggesting the need for continued multidisciplinary rehabilitation.

31 March 2026 in Medicine and Biotechnology
Verified
Journal Article
Open access
PDF file
KAKarim Aly Zaky Atta
Karim Aly Zaky Atta
VDVasily I. Davydkin
Vasily I. Davydkin
MAMohamed Saed Mohamed AbdelAziz
Mohamed Saed Mohamed AbdelAziz
ASAhmed Mohamed Fathy Sobhy
Ahmed Mohamed Fathy Sobhy
AAAbdelaziz Abdelaziz
Abdelaziz Abdelaziz
Introduction. Beta-blockers are commonly prescribed after myocardial infarction; however, their benefit in patients without heart failure and with preserved left ventricular ejection fraction in the modern era of reperfusion therapy remains unclear. The aim of the study is to evaluate the effect of beta-blockers on clinical outcomes in patients without heart failure.Materials and methods. The authors conducted a systematic review and meta-analysis of randomized controlled trials evaluating beta-blocker therapy after discharge in patients with myocardial infarction without clinical manifestations of heart failure. Searches in PubMed, Scopus, Web of Science, and Cochrane CENTRAL were performed in February 2026. The primary outcome was major adverse cardiovascular and cerebrovascular events. Secondary outcomes included mortality, recurrent myocardial infarction, heart failure, revascularization, and stroke. Hazard ratios with 95% confidence intervals were pooled using a random-effects model.Results. Four randomized controlled trials including 19,826 patients were analyzed. Beta-blocker therapy was not associated with a significant reduction in the incidence of major adverse cardiovascular and cerebrovascular events (hazard ratio 0.98, 95% confidence interval: 0.91–1.06, p = 0.64) or any of the secondary outcomes: all-cause mortality (hazard ratio 0.98, 95% confidence interval: 0.85–1.13, p = 0.78), recurrent myocardial infarction (hazard ratio 0.88, 95% confidence interval: 0.72–1.07, p = 0.20), heart failure (hazard ratio 0.82, 95% confidence interval: 0.63–1.07, p = 0.14), revascularization (hazard ratio 1.01, 95% confidence interval: 0.87–1.17, p = 0.86), or stroke (hazard ratio 1.24, 95% confidence interval: 0.97–1.59, p = 0.09). Discussion and conclusion. In patients with acute myocardial infarction without heart failure and with preserved left ventricular function, routine beta-blocker therapy after discharge was not associated with a reduction in the incidence of major adverse cardiovascular and cerebrovascular events or their individual components in the context of contemporary reperfusion therapy. Further large-scale studies are required to develop individualized therapeutic approaches.

11 May 2026 in World Journal for Pediatric and Congenital Heart Surgery
Verified
Journal Article
Closed access
KAKarim Atta
Karim Atta
AAAbdelaziz Abdelaziz
Abdelaziz Abdelaziz
SRShrouk Ramadan
Shrouk Ramadan
AGAhmed Farid Gadelmawla
Ahmed Farid Gadelmawla
MMMohamed R. Murad
Mohamed R. Murad
ESElena Semenovna Samoshkina
Elena Semenovna Samoshkina
Background: Congenital aortic valve stenosis (AVS) is the most common cause of ventricular outflow tract obstruction. Surgical aortic valvuloplasty (SAV) and balloon aortic valvuloplasty (BAV) are the most common primary interventions, with conflicting data regarding their long-term outcomes. We aimed to study the long-term clinical outcomes of patients allocated to BAV or SAV. Methods: We searched PubMed, Scopus, Web of Science, and Cochrane CENTRAL through August 2025 for relevant studies reporting long-term outcomes of SAV versus BAV in patients with congenital AVS. The primary outcome was the 10-year rate of aortic valve replacement (AVR). Subgroup analysis was performed for all clinical outcomes according to the age of the included children. Results: A total of nine trials including 1704 patients (67%, [1136/1704]) males; median follow-up of 10 years) were included. The pooled estimate showed that SAV was associated with lower long-term reintervention rates (risk ratio 0.76, 95% confidence interval (CI): 0.6 to 0.96, P = .02), and a significant reduction in peak aortic gradient pressure (PAGP) (mean difference (MD) −11.53 mm Hg, 95% CI: −18.66 to −4.41, P < .001) in patients more than 1 year of age. In addition, SAV was associated with a longer time to first reintervention in patients younger than 1 year of age (MD 2.43 years, 95% CI: 0.68 to 4.19, P = .01). There was no significant difference regarding the primary outcome or other studied outcomes. Conclusion: In patients with congenital aortic valve stenosis, SAV showed the greatest benefit in children older than 1 year of age with similar AVR and mortality rates; but superior durability, lower reintervention rates, and greater reductions in peak aortic pressure gradient when compared with BAV.

9 October 2026 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Open access
PDF file
ANAhmed Nazmy
Ahmed Nazmy
AAAlaa Abdrabou Abouelmagd
Alaa Abdrabou Abouelmagd
ASAhmed Sobhy
Ahmed Sobhy
MAMennatullah Ashour
Mennatullah Ashour
HEHassan El-Shirbiny
Hassan El-Shirbiny
C Michael GibsonC Michael Gibson
C Michael Gibson
Background: Left atrial appendage occlusion (LAAO) has emerged as a non‐pharmacological alternative to oral anticoagulation (OAC) for stroke prevention in patients with atrial fibrillation (AF). Following the publication of recent CHAMPION‐AF and CLOSURE‐AF trials, an updated synthesis of evidence is warranted to clarify the long‐term comparative efficacy and safety of LAAO versus OAC in patients with AF. Methods: We conducted a systematic review and meta‐analysis of randomized controlled trials (RCTs) comparing LAAO with OAC in adults with AF. A comprehensive search of major databases was performed from inception to April 2026. The primary efficacy outcomes were major adverse cardiovascular events (MACE) and stroke. The primary safety outcome was non–procedure‐related bleeding. Random‐effects models were used to calculate pooled risk ratios (RRs) with 95% confidence intervals (CIs). Results: Six RCTs including 7,004 patients (3,681 LAAO; 3,323 OAC) were analyzed. No statistically significant difference was observed for MACE (7.5% vs 6.9%; RR 1.03, 95% CI 0.79‐1.34) or stroke (3.7% vs 3.2%; RR 1.07, 95% CI 0.80‐1.43). LAAO was associated with a significantly lower risk of non‐procedure‐related bleeding (9.8% vs 16.7%; RR 0.63, 95% CI 0.52‐0.77), corresponding to an absolute risk reduction of 6.9% and an approximate number needed to treat of 15 based on crude pooled event rates over the observed trial follow‐up. Trial sequential analysis indicated that the accumulated evidence for MACE and stroke remained inconclusive. Comparator‐type subgroup analyses showed no significant interaction for MACE ( p = 0.67) or stroke ( p = 0.81) between contemporary predominantly‐DOAC and VKA comparator trials. Conclusions: LAAO was associated with lower non‐procedure‐related bleeding, while no statistically significant differences were observed for MACE or stroke. The available efficacy evidence remains inconclusive regarding equivalence or non‐inferiority, and larger trials are needed. These findings support individualized consideration of LAAO when the long‐term bleeding burden of anticoagulation is clinically important.